• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

  • Print
  • Share
  • E-mail
-

Patent and Exclusivity Search Results from query on Appl No 202611 Product 002 in the OB_Rx list.


Patent Data

Appl No Prod No Patent No Patent
Expiration
Drug Substance
Claim
Drug Product
Claim
Patent Use
Code
Delist
Requested
N202611 002 6346532 Oct 15, 2018 Y Y
N202611 002 6562375 Aug 1, 2020 Y
N202611 002 6699503 Sep 10, 2013 Y
N202611 002 7342117 Nov 4, 2023 Y
N202611 002 7750029 Dec 18, 2023 U - 913
N202611 002 7982049 Nov 4, 2023 Y
N202611 002 8835474 Nov 4, 2023 U - 1527
N202611 002 RE44872 Dec 18, 2023 U - 1527

Exclusivity Data

Appl No Prod No Exclusivity Code Exclusivity Expiration
N202611 002 NCE Jun 28, 2017


Additional information:

  1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
  2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. These patents may not be flagged with respect to other claims which may apply.


View a list of all patent use codes
View a list of all exclusivity codes

Return to Electronic Orange Book Home Page


FDA/Center for Drug Evaluation and Research
Office of Generic Drugs
Division of Labeling and Program Support
Update Frequency:

Orange Book Data - Monthly
Generic Drug Product Information & Patent Information - Daily
Orange Book Data Updated Through November 2014
Patent and Generic Drug Product Data Last Updated December 19, 2014

-
-